Equity Overview
Price & Market Data
Price: $1.46
Daily Change: +$0.02 / 1.37%
Range: $1.40 - $1.47
Market Cap: $99,827,504
Volume: 4,684
Performance Metrics
1 Week: 23.91%
1 Month: -4.36%
3 Months: -17.15%
6 Months: -70.50%
1 Year: -56.95%
YTD: -43.00%
Company Details
Employees: 30
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33. Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.